{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:11:52Z","timestamp":1789506712716,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004697","name":"Hamadan University of Medical Sciences","doi-asserted-by":"publisher","award":["140209077543"],"award-info":[{"award-number":["140209077543"]}],"id":[{"id":"10.13039\/501100004697","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.vaccine.2026.128868","type":"journal-article","created":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T11:53:42Z","timestamp":1781956422000},"page":"128868","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Clinical outcomes among SARS-CoV-2 omicron-infected adults according to prior infection and vaccination history in Iran: A retrospective registry-based study"],"prefix":"10.1016","volume":"88","author":[{"given":"Fateme","family":"Torkaman-Asadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somaye","family":"Bakhtiari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrnoush","family":"Safarzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Riahi-Rad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zohreh","family":"Riahi-Rad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"Doosti Irani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nastaran","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128868_bb0005","series-title":"SARS-CoV-2 emerging Omicron subvariants with a special focus on BF. 7 and XBB. 1.5 recently posing fears of rising cases amid ongoing COVID-19 pandemic","author":"Dhama","year":"2022"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128868_bb0010","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.cell.2022.12.018","article-title":"Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants","volume":"186","author":"Wang","year":"2023","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128868_bb0015","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1056\/NEJMc2214293","article-title":"Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA bivalent booster","volume":"388","author":"Davis-Gardner","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128868_bb0020","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/s41467-023-36561-6","article-title":"Resistance of omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies","volume":"14","author":"Planas","year":"2023","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128868_bb0025","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1097\/JS9.0000000000000246","article-title":"The SARS-CoV-2 omicron recombinant subvariants XBB, XBB.1, and XBB.1.5 are expanding rapidly with unique mutations, antibody evasion, and immune escape properties - an alarming global threat of a surge in COVID-19 cases again?","volume":"109","author":"Chakraborty","year":"2023","journal-title":"Int J Surg"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128868_bb0030","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.263","article-title":"A recombinant spike-XBB.1.5 protein vaccine induces broad-spectrum immune responses against XBB.1.5-included omicron variants of SARS-CoV-2","volume":"4","author":"He","year":"2023","journal-title":"MedComm"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128868_bb0035","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/j.jiph.2020.07.014","article-title":"COVID-19 and comorbidities: deleterious impact on infected patients","volume":"13","author":"Ejaz","year":"2020","journal-title":"J Infect Public Health"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128868_bb0040","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3319","article-title":"Diabetes is a risk factor for the progression and prognosis of COVID-19","volume":"36","author":"Guo","year":"2020","journal-title":"Diabetes Metab Res Rev"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128868_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.08.017","article-title":"Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19","volume":"183","author":"Sekine","year":"2020","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128868_bb0050","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1038\/s41564-020-00813-8","article-title":"Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans","volume":"5","author":"Seow","year":"2020","journal-title":"Nat Microbiol"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128868_bb0055","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/s41591-022-01699-1","article-title":"Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England","volume":"28","author":"Andrews","year":"2022","journal-title":"Nat Med"},{"issue":"6561","key":"10.1016\/j.vaccine.2026.128868_bb0060","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1126\/science.abj4176","article-title":"Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants","volume":"373","author":"Pegu","year":"2021","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128868_bb0065","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1473-3099(22)00578-3","article-title":"Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study","volume":"23","author":"Carazo","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"23","key":"10.1016\/j.vaccine.2026.128868_bb0070","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1056\/NEJMoa2118946","article-title":"Protection and waning of natural and hybrid immunity to SARS-CoV-2","volume":"386","author":"Goldberg","year":"2022","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128868_bb0075","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.3390\/vaccines11081376","article-title":"A comparative study of immunogenicity, antibody persistence, and safety of three different COVID-19 boosters between individuals with comorbidities and the normal population","volume":"11","author":"Ashrafian","year":"2023","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2026.128868_bb0080","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.878159","article-title":"SARS-CoV-2 omicron variant: exploring healthcare workers\u2019 awareness and perception of vaccine effectiveness: a national survey during the first week of WHO variant alert","volume":"10","author":"Temsah","year":"2022","journal-title":"Front Public Health"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128868_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7774\/cevr.2023.12.1.1","article-title":"Exploring the experience of developing COVID-19 vaccines in Iran","volume":"12","author":"Ghanei","year":"2023","journal-title":"Clin Experimen Vaccine Res"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128868_bb0090","first-page":"119","article-title":"Evolution of SARS-CoV-2; the omicron variant and its considerations, a Mini review","volume":"8","author":"Firouzabadi","year":"2022","journal-title":"Trends Pharma Sci Technol"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128868_bb0095","doi-asserted-by":"crossref","DOI":"10.1111\/irv.13135","article-title":"Genomic surveillance of SARS-CoV-2 strains circulating in Iran during six waves of the pandemic","volume":"17","author":"Sadeghi","year":"2023","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.vaccine.2026.128868_bb0100","series-title":"WHO COVID-19: case definitions: updated in Public health surveillance for COVID-19, 22 July 2022","author":"Organization WH","year":"2022"},{"issue":"13","key":"10.1016\/j.vaccine.2026.128868_bb0105","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa2118691","article-title":"Protection against SARS-CoV-2 after Covid-19 vaccination and previous infection","volume":"386","author":"Hall","year":"2022","journal-title":"N Engl J Med"},{"issue":"7867","key":"10.1016\/j.vaccine.2026.128868_bb0110","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41586-021-03647-4","article-title":"SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans","volume":"595","author":"Turner","year":"2021","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128868_bb0115","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41577-022-00725-0","article-title":"SARS-CoV-2: from herd immunity to hybrid immunity","volume":"22","author":"Goldblatt","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2026.128868_bb0120","series-title":"SARS-CoV-2 hybrid immunity: The best of both worlds","first-page":"1311","author":"Lasrado","year":"2023"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128868_bb0125","doi-asserted-by":"crossref","first-page":"6478","DOI":"10.1038\/s41467-022-33864-y","article-title":"Analysis of anti-SARS-CoV-2 omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources","volume":"13","author":"Sullivan","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128868_bb0130","doi-asserted-by":"crossref","first-page":"4738","DOI":"10.1038\/s41467-022-31838-8","article-title":"Protection of COVID-19 vaccination and previous infection against omicron BA. 1, BA. 2 and Delta SARS-CoV-2 infections","volume":"13","author":"Andeweg","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2026.128868_bb0135","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ijid.2021.11.009","article-title":"Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis","volume":"114","author":"Zheng","year":"2022","journal-title":"Int J Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128868_bb0140","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1093\/cid\/ciac634","article-title":"Effectiveness of coronavirus disease 2019 vaccines against hospitalization and death in Canada: a multiprovincial, test-negative design study","volume":"76","author":"Nasreen","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128868_bb0145","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2108891","article-title":"Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant","volume":"385","author":"Lopez Bernal","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128868_bb0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0320779","article-title":"Vaccine effectiveness of inactivated and mRNA COVID-19 vaccine platform during Delta and omicron wave in Jakarta, Indonesia: a test-negative case-control study","volume":"20","author":"Burhan","year":"2025","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128868_bb0155","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S1473-3099(22)00801-5","article-title":"Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression","volume":"23","author":"Bobrovitz","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"10328","key":"10.1016\/j.vaccine.2026.128868_bb0160","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0140-6736(22)00152-0","article-title":"Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression","volume":"399","author":"Feikin","year":"2022","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128868_bb0165","doi-asserted-by":"crossref","first-page":"15612","DOI":"10.1038\/s41598-022-19993-w","article-title":"Reevaluation of antibody-dependent enhancement of infection in anti-SARS-CoV-2 therapeutic antibodies and mRNA-vaccine antisera using FcR-and ACE2-positive cells","volume":"12","author":"Shimizu","year":"2022","journal-title":"Sci Rep"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26006778?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26006778?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:44:05Z","timestamp":1789505045000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26006778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":33,"alternative-id":["S0264410X26006778"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128868","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical outcomes among SARS-CoV-2 omicron-infected adults according to prior infection and vaccination history in Iran: A retrospective registry-based study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128868","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"128868"}}